- Home
- TLPH vs CSCI Comparison
TLPH vs CSCI Comparison
Compare TLPH & CSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- CSCI
- Stock Information
- Founded
- TLPH 2005
- CSCI 1990
- Country
- TLPH United States
- CSCI Canada
- Employees
- TLPH N/A
- CSCI N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- CSCI
- Sector
- TLPH Health Care
- CSCI
- Exchange
- TLPH Nasdaq
- CSCI NYSE
- Market Cap
- TLPH 12.7M
- CSCI 11.1M
- IPO Year
- TLPH 2011
- CSCI 1996
- Fundamental
- Price
- TLPH $0.63
- CSCI $2.80
- Analyst Decision
- TLPH Strong Buy
- CSCI
- Analyst Count
- TLPH 2
- CSCI 0
- Target Price
- TLPH $4.50
- CSCI N/A
- AVG Volume (30 Days)
- TLPH 101.8K
- CSCI 12.4K
- Earning Date
- TLPH 03-05-2025
- CSCI 03-26-2025
- Dividend Yield
- TLPH N/A
- CSCI N/A
- EPS Growth
- TLPH N/A
- CSCI N/A
- EPS
- TLPH N/A
- CSCI N/A
- Revenue
- TLPH $281,000.00
- CSCI $4,834,000.00
- Revenue This Year
- TLPH N/A
- CSCI N/A
- Revenue Next Year
- TLPH N/A
- CSCI N/A
- P/E Ratio
- TLPH N/A
- CSCI N/A
- Revenue Growth
- TLPH N/A
- CSCI N/A
- 52 Week Low
- TLPH $0.50
- CSCI $2.38
- 52 Week High
- TLPH $1.61
- CSCI $11.10
- Technical
- Relative Strength Index (RSI)
- TLPH 46.28
- CSCI N/A
- Support Level
- TLPH $0.54
- CSCI N/A
- Resistance Level
- TLPH $0.73
- CSCI N/A
- Average True Range (ATR)
- TLPH 0.07
- CSCI 0.00
- MACD
- TLPH -0.00
- CSCI 0.00
- Stochastic Oscillator
- TLPH 31.46
- CSCI 0.00
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.